tetravalent rna-lipoplex cancer vaccine bnt111
Generic: Tetravalent RNA-lipoplex Cancer Vaccine BNT111
tetravalent rna-lipoplex cancer vaccine bnt111: 1 clinical trial tracked.
tetravalent rna-lipoplex cancer vaccine bnt111 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about tetravalent rna-lipoplex cancer vaccine bnt111, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
Primary endpoint: Arm 1: Objective Response Rate (ORR)
InterventionalRandomizedopen184 enrolledStarted 2021-05Completion 2025-1149 sites · Australia, Germany, Italy, Poland…BioNTech SE